Karyopharm to Merge With Ayrmid Ltd. in Bid to Survive Cash Crunch
KPTI sits 98% above its 52-week low of $0.31.
Summary
Karyopharm announced a planned merger with Ayrmid Ltd., a deal framed as strengthening the company for the future, and Ayrmid will serve as lead bidder in a court-supervised sale process. The move comes with the company under severe financial strain: Q2 2026 losses widened to $67 million, cash was projected to run only into September 2026, and the company missed a $15.8 million debt payment in September, entering forbearance with creditors. That forbearance has already been extended twice, most recently from October 22 to November 1, 2026, so the merger is the company's path out of a liquidity crisis rather than a growth deal. Karyopharm has now filed Chapter 11 and agreed to the Ayrmid merger. Terms, exchange ratio, and financing were not disclosed in the headline, leaving dilution and creditor treatment as the key unknowns. The stock trades near $0.61 with a micro-cap valuation, so the merger terms will dominate the equity story.
At the time of this announcement, KPTI was trading at $0.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15M. The 52-week trading range was $0.31 to $10.99. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.